There’s an App for That: FDA Launches Orange Book Express App

November 11, 2015

On November 9, 2015, FDA launched the Orange Book Express application, which provides a list of the drug products approved by the FDA.

What is the Orange Book?

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, was passed to encourage and simplify the development of generic products for pharmaceutical companies. The Act required FDA to publish a list of Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book).

The Orange Book first appeared as a print publication in October 1980 and provided information about innovator and generic drug product approvals. On October 31, 1997,FDA added the Orange Book Search to its website. Since 2005, the Electronic Orange Book (EOB) has been updated on a daily basis with a current list of approved generic products.

Today, that list includes:

  • All drug products approved by FDA on the basis of safety and efficacy
    • Drugs approved only on the basis of safety are not included in the book
  • Therapeutic equivalence evaluations for approved generic drugs
  • Patent and exclusivity information that may be associated with drug products

The Orange Book is one of the most popular pages on FDA’s website; it is also one of the most commonly searched terms.

Orange Book Express Mobile Application

The recently released mobile app is compatible with both Apple® and Android TM devices. It provides users with access to timely information about innovator and generic drugs and provides an easy and convenient way to obtain the Orange Book’s information. The app is very user friendly and lets users search by active ingredient, proprietary name, applicant holder, application number, and patent number.

Search results are organized into tabs which show product records from the Prescription Drug Product List, the Over-the-Counter Drug Product List, and the Discontinued Drug Product List from the Orange Book. Additionally, all product entries contain the same links to patent and exclusivity information that is listed in the electronic and paper versions of the Orange Book.

The main difference between the two versions (app vs. online) is the app’s inability to filter results and search for text within the results. However, the app includes a link to the Orange Book website enabling users to have direct access to all of the information that is available from the current website version.

For more information, visit the FDA’s website.

TAGS:

July 30, 2018

FDA Releases Draft Guidance on Nonprescription Drugs

On Tuesday, July 17th, FDA released a new draft guidance entitled “Innovative Approaches for Nonprescription Drug Products.” The guidance discusses two different approaches for making nonprescription...

July 3, 2018

FDA Approves First Marijuana-Derived Drug for the Treatment of Epilepsy

On Monday, June 25th, FDA approved GW Pharmaceuticals’ Epidiolex (cannabidiol) for the treatment of two rare and severe forms of epilepsy. Epidiolex is the first FDA-approved drug that contains a...

July 12, 2017

FDA Approves 1st Drug for Sickle Cell Disease in Nearly 20 Years

On Friday, July 7th, the FDA approved Endari (L-glutamine oral powder) to reduce the complications associated with sickle cell disease in patients age five years and older. What is Sickle Cell...